SDZ MKS 492Alternative Names: MKS 492
Latest Information Update: 15 Jun 1995
At a glance
- Originator Novartis
- Mechanism of Action Phosphoric diester hydrolase inhibitors
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Discontinued Asthma
Most Recent Events
- 15 Jun 1995 Discontinued-I for Asthma in United Kingdom (Inhalation)
- 15 Jun 1995 Discontinued-I for Asthma in United Kingdom (PO)
- 15 Jun 1995 Discontinued-I for Asthma in Switzerland (PO)